Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation.

OBJECTIVE Expression of the immunoreactive protein of matrix metalloproteinase 2 (MMP-2) was studied in cervical tumors representing various stages of cell atypia and differentiation. In this study, we evaluated whether the expression of MMP-2 is an early or late event in the process of dedifferentiation and cancer progression. METHODS Paraffin tissue sections from 60 cervical neoplasias including 38 cervical intraepithelial neoplasias (CINs) and 22 early-stage (stage IB and IIA) squamous cervical carcinomas were studied with respect to the expression of MMP-2 protein by using immunoperoxidase staining. RESULTS The staining pattern of MMP-2 in the CIN lesions usually differed from that in squamous carcinoma. Latent MMP-2 protein localized, in most of the cases, to the periphery of the CIN cells, but was diffuse in the cytoplasm of the carcinoma cells. No correlation was found between overexpression of MMP-2 protein and degree of dysplasia, nor was there any association between MMP-2 and human papillomavirus (HPV). High scores for MMP-2 were observed only in histologically higher-grade early-stage cervical carcinomas. The lymph node metastases derived from high-MMP-2-score primary tumors were also positive for MMP-2. No correlation between MMP-2 staining and clinical course or prognosis was found. CONCLUSIONS MMP-2 expression is an early event during dedifferentiation and malignant transformation in cervical neoplasias. The pattern of staining is different in CIN than in squamous carcinoma cells, in which overexpression may correlate with the degree of anaplasia.

[1]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[2]  L. Liotta,et al.  Immunohistochemical localization of matrix metallloproteinase 2 and its specific inhibitor timp‐2 in neoplastic tissues with monclonal antibodies , 1994, International journal of cancer.

[3]  J. Foidart,et al.  High level of MT‐MMP expression is associated with invasiveness of cervical cancer cells , 1996, International journal of cancer.

[4]  G. Nuovo In situ detection of PCR‐amplified metalloproteinase cDNAS, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines , 1997, International journal of cancer.

[5]  C. Romanini,et al.  The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement. , 1996, Gynecologic oncology.

[6]  L. Liotta,et al.  Modulation of type‐iv collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type‐iv collagenase , 1990, International journal of cancer.

[7]  L. Liotta,et al.  Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. , 1985, Journal of the National Cancer Institute.

[8]  J. Vandenbroucke,et al.  Cervical carcinoma in surinam , 1996 .

[9]  T. Turpeenniemi‐Hujanen,et al.  Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro , 1991, International journal of cancer.

[10]  T. Hurskainen,et al.  Simultaneous expression of 70 kilodalton type IV collagenase and type IV collagen alpha 1 (IV) chain genes by cells of early human placenta and gestational endometrium. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[11]  T. Hurskainen,et al.  Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[12]  M. Kallioinen,et al.  Prognostic value of MMP‐2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma , 1998, The Journal of pathology.

[13]  L. Liotta,et al.  Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[14]  H. Jonsson,et al.  Pap smear screening and changes in cervical cancer mortality in Sweden , 1994, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[15]  M. Kallioinen,et al.  MATRIX METALLOPROTEINASE‐2 (72 kD TYPE IV COLLAGENASE) EXPRESSION OCCURS IN THE EARLY STAGE OF HUMAN MELANOCYTIC TUMOUR PROGRESSION AND MAY HAVE PROGNOSTIC VALUE , 1996, The Journal of pathology.

[16]  L. Liotta,et al.  Metastatic potential correlates with enzymatic degradation of basement membrane collagen , 1980, Nature.

[17]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase‐2 immunoreactive protein , 1998, Cancer.

[18]  M. Hakama,et al.  A screening programme for cervical cancer that worked. , 1988, Cancer surveys.

[19]  L. Liotta,et al.  Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. , 1990, The American journal of pathology.

[20]  A. Ciavattini,et al.  Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. , 1996, Gynecologic oncology.

[21]  W. Stetler-Stevenson,et al.  The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. , 1994, The European respiratory journal.

[22]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  T. Turpeenniemi‐Hujanen,et al.  Modulation of Mr 72,000 and Mr 92,000 type‐IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma , 1994, International journal of cancer.

[24]  L. Liotta,et al.  Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.